<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.2d1 20170631//EN" "JATS-journalpublishing1.dtd">
<article xlink="http://www.w3.org/1999/xlink" dtd-version="1.0" article-type="emergency-medicine-and-critical-care" lang="en">
  <front>
    <journal-meta>
      <journal-id journal-id-type="publisher">JOHS</journal-id>
      <journal-id journal-id-type="nlm-ta">Journ of Health Scien</journal-id>
      <journal-title-group>
        <journal-title>Journal of HealthCare Sciences</journal-title>
        <abbrev-journal-title abbrev-type="pubmed">Journ of Health Scien</abbrev-journal-title>
      </journal-title-group>
      <issn pub-type="ppub">2231-2196</issn>
      <issn pub-type="opub">0975-5241</issn>
      <publisher>
        <publisher-name>Radiance Research Academy</publisher-name>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="publisher-id">28</article-id>
      <article-id pub-id-type="doi">https://dx.doi.org/10.52533/JOHS.2021.1502</article-id>
      <article-id pub-id-type="doi-url"/>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Emergency Medicine and Critical Care</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Role of Recombinant Human Granulocyte-Macrophage Colony-Stimulating Factor (rhGM-CSF) in Wound Healing in Critical Care Settings&#13;
</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Moharag</surname>
            <given-names>Abdulmajeed</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mansouri</surname>
            <given-names>Albatool</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Althaqafi</surname>
            <given-names>Bashayer</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Halawani</surname>
            <given-names>Julnar</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Banjar</surname>
            <given-names>Haneen</given-names>
          </name>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Alnaim</surname>
            <given-names>Muna</given-names>
          </name>
        </contrib>
      </contrib-group>
      <pub-date pub-type="ppub">
        <day>30</day>
        <month>11</month>
        <year>-0001</year>
      </pub-date>
      <volume>1</volume>
      <issue>5</issue>
      <fpage>126</fpage>
      <lpage>132</lpage>
      <permissions>
        <copyright-statement>This article is copyright of Popeye Publishing, 2009</copyright-statement>
        <copyright-year>2009</copyright-year>
        <license license-type="open-access" href="http://creativecommons.org/licenses/by/4.0/">
          <license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution (CC BY 4.0) Licence. You may share and adapt the material, but must give appropriate credit to the source, provide a link to the licence, and indicate if changes were made.</license-p>
        </license>
      </permissions>
      <abstract>
        <p>Surgical management for burns has been reported to effectively manage such cases via early excisions and grafting to enhance re-epithelization. However, the operation is very expensive and not be suitable for many patients, especially those suffering from extensive body burns across huge surface areas. Recombinant human granulocyte-macrophage colony-stimulating factor has been validated to effectively manage severe burns, resulting in favorable outcomes and minimal or absent adverse events. Recombinant human granulocyte-macrophage colony-stimulating factor should be used for the management of such patients due to the favorable events that have been extensively reported among studies in the literature. Some of these events include reducing the healing time and increasing the rates of wound healing among burns patients, when compared to other treatment modalities. Additionally, various studies have also demonstrated that no significant adverse events are associated with it, adding to its efficacy in the management of deep burns. However, it should be noted that further research is still encouraged to further validate the current evidence, and to validate the effect on scarring. Further details are discussed within the manuscript.&#13;
</p>
      </abstract>
      <kwd-group>
        <kwd>granulocyte stimulating factor</kwd>
        <kwd>rhGM-CSF</kwd>
        <kwd>burns</kwd>
        <kwd>management</kwd>
        <kwd>efficacy</kwd>
      </kwd-group>
    </article-meta>
  </front>
</article>